Microgynon 30 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the estrogen component, suppresses the pituitary release of follicle‑stimulating hormone, which together with levonorgestrel’s inhibition of luteinising hormone prevents ovulation. This hormonal balance also contributes to cervical mucus thickening and endometrial changes that reduce the chance of fertilisation and implantation.

The dosing regimen for Microgynon 30 is determined by the prescribing clinician. Typically, the product is taken once daily as directed, following the specific cycle schedule indicated on the prescription label.

Microgynon 30 is contraindicated in pregnancy (Category X) and should not be started or continued by women who are pregnant. While limited data exist for breastfeeding, most guidelines advise caution and recommend discussing alternatives with a healthcare professional.

To order Microgynon 30, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microgynon 30 contains 30 µg ethinylestradiol and 150 µg levonorgestrel, a dose combination that balances efficacy with a lower risk of estrogen‑related side effects compared with higher‑dose formulations. Its safety and effectiveness profile is comparable to other second‑generation combined pills, but individual tolerability may vary.

Store Microgynon 30 at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and ensure they are out of reach of children.

Microgynon 30 is taken orally, usually once each day at the same time. The tablets are swallowed with water and should be taken as directed by the prescriber, following the prescribed cycle of active and placebo tablets.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, and severe allergic reactions. These events are rare but require immediate medical attention if symptoms such as sudden chest pain, shortness of breath, severe headache, or swelling of the limbs occur.

Microgynon 30 should not be used by women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, certain hormone‑dependent cancers, severe liver disease, or who smoke heavily (more than 15 cigarettes per day) and are over 35 years of age.